Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Acquired by Harel Insurance Investments & Financial Services Ltd.

Harel Insurance Investments & Financial Services Ltd. boosted its stake in Medpace Holdings, Inc. (NASDAQ:MEDP) by 28.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 15,543 shares of the company’s stock after acquiring an additional 3,410 shares during the period. Harel Insurance Investments & Financial Services Ltd.’s holdings in Medpace were worth $5,164,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Pallas Capital Advisors LLC increased its holdings in shares of Medpace by 179.7% in the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock valued at $1,086,000 after purchasing an additional 2,101 shares during the period. Baillie Gifford & Co. grew its position in Medpace by 175.6% in the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after buying an additional 9,478 shares during the last quarter. Barclays PLC increased its stake in Medpace by 71.9% in the 3rd quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after buying an additional 8,275 shares during the period. Oppenheimer Asset Management Inc. raised its position in Medpace by 6.3% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after buying an additional 2,675 shares during the last quarter. Finally, CWA Asset Management Group LLC acquired a new stake in shares of Medpace in the 3rd quarter worth $1,306,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Price Performance

Shares of MEDP opened at $344.07 on Friday. The company has a 50-day moving average of $339.66 and a two-hundred day moving average of $356.00. Medpace Holdings, Inc. has a one year low of $286.76 and a one year high of $459.77. The stock has a market cap of $10.69 billion, a price-to-earnings ratio of 30.13, a PEG ratio of 1.77 and a beta of 1.36.

Analyst Upgrades and Downgrades

Several research firms have issued reports on MEDP. StockNews.com cut Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. William Blair reaffirmed an “outperform” rating on shares of Medpace in a report on Tuesday, October 22nd. Truist Financial reduced their target price on Medpace from $415.00 to $397.00 and set a “hold” rating for the company in a report on Monday, October 14th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $420.00 to $350.00 in a research note on Friday, September 27th. Finally, Baird R W cut shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and an average price target of $380.56.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.